CTRI/2012/10/003066进行中（未招募）3 期
A multi-centre 3-year follow-up study to assess thedurability of sustained virologic response in Alisporivir treatedchronic Hepatitis C patients
ovartis Healthcare Pvt Lt0 个研究点目标入组 2,000 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 2,000
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
入选标准
- •1. Written informed consent must be obtained before any assessment is performed.
- •3. Have previously completed a Novartis-sponsored hepatitis C study and received
- •alisporivir
- •4. Have achieved SVR24
- •5. Are able to comply with the visit schedule
排除标准
- •1. Use of any investigational drugs within 5 half-lives of enrollment, or within 30 days of
- •that medication, whichever is longer.
- •2. Use or planned use to start a new course of hepatitis C therapy
研究者
相似试验
进行中（未招募）
1 期
A 3-year follow-up study in chronic hepatitis C patients who failed to achieve sustained virologic response during Novartis-sponsored alisporivir studiesChronic hepatitis C patients who failed to achieve sustained virologic response (SVR24) on alisporivir or direct-acting antivirals (DAA) in previous Novartis-sponsored studies.MedDRA version: 14.1Level: SOCClassification code 10021881Term: Infections and infestationsSystem Organ Class: 10021881 - Infections and infestationsEUCTR2011-006132-24-GBovartis Pharma Services AG105
进行中（未招募）
不适用
A 3-year follow-up study in chronic hepatitis C patients who failed to achieve sustained virologic response during Novartis-sponsored alisporivir studiesEUCTR2011-006132-24-HUovartis Pharma Services AG650
进行中（未招募）
不适用
A 3-year follow-up study of chronic hepatitis C patients treated with alisporivir to assess durability of sustained virologic responseEUCTR2011-006131-38-GBovartis Pharma Services AG2,000
进行中（未招募）
不适用
A 3-year follow-up study in chronic hepatitis C patients who failed to achieve sustained virologic response during Novartis-sponsored alisporivir studiesChronic hepatitis C patients who failed to achieve sustained virologic response (SVR24) on alisporivir or direct-acting antivirals (DAA) in previous Novartis-sponsored studies.MedDRA version: 14.1Level: SOCClassification code 10021881Term: Infections and infestationsSystem Organ Class: 10021881 - Infections and infestationsEUCTR2011-006132-24-ESovartis Farmaceutica, S.A.650
进行中（未招募）
不适用
A 3-year follow-up study of chronic hepatitis C patients treated with alisporivir to assess durability of sustained virologic responseEUCTR2011-006131-38-ITOVARTIS FARMA2,000